X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The gross proceeds will be used to fund the clinical development of SerpinPC, which is being evaluated in the mid-stage clinical trial for the treatment of Hemophilia A and Hemophilia B.
Lead Product(s): SerpinPC
Therapeutic Area: Genetic Disease Product Name: SerpinPC
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Goldman Sachs
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering April 23, 2024
Details:
ORX750 is an investigational, orally administered, highly potent and selective orexin receptor 2 (OX2R) agonist designed to directly target the underlying pathophysiology of orexin neuron loss in narcolepsy type 1 (NT1).
Lead Product(s): ORX750
Therapeutic Area: Sleep Product Name: ORX750
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 22, 2024
Details:
Under the terms of the agreement, Anaptys will receive from Centessa an exclusive, global license for ANB101 (CBS004), a potentially best-in-class BDCA2 modulator antibody that targets pDCs and ANB102, an extended half-life BDCA2 modulator.
Lead Product(s): CBS004
Therapeutic Area: Immunology Product Name: ANB101
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: AnaptysBio
Deal Size: Undisclosed Upfront Cash: $10.0 million
Deal Type: Licensing Agreement November 27, 2023
Details:
ORX750 is an investigational, orally administered, highly potent and selective orexin receptor 2 (OX2R) agonist designed to directly target the underlying pathophysiology of orexin neuron loss in narcolepsy type 1 (NT1).
Lead Product(s): ORX750
Therapeutic Area: Sleep Product Name: ORX750
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 25, 2023
Details:
SerpinPC is designed to allow more thrombin to be generated by inhibiting activated protein C (APC) thus rebalancing coagulation in hemophilia A patients.
Lead Product(s): SerpinPC
Therapeutic Area: Genetic Disease Product Name: SerpinPC
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 06, 2023
Details:
LB101 is a conditionally tetravalent PD-L1xCD47 LockBody bispecific monoclonal antibody which has two anti-CD47 domains blocked by two anti-PD-L1 domains, with proprietary human IgG-derived hinges linking the anti-CD47 and anti-PD-L1 domains.
Lead Product(s): LB101
Therapeutic Area: Oncology Product Name: LB101
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 26, 2023
Details:
SerpinPC, a biologic based on the serpin family of proteins, is designed to allow more thrombin to be generated by inhibiting activated protein C (APC) thus rebalancing coagulation in hemophilia patients.
Lead Product(s): SerpinPC
Therapeutic Area: Genetic Disease Product Name: SerpinPC
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 10, 2022
Details:
The data further extend the six-month data we shared last year from the Phase 2a study, where a subcutaneous dose of 1.2 mg/kg once every 4 weeks of SerpinPC demonstrated an 88% reduction in the median annualized bleeding rate for all bleeds and was well tolerated in patients.
Lead Product(s): SerpinPC
Therapeutic Area: Genetic Disease Product Name: SerpinPC
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2022
Details:
SerpinPC is a biological drug candidate, based on the serpin family of proteins that is designed to allow more thrombin to be generated by inhibiting APC, thus rebalancing coagulation in hemophilia patients.
Lead Product(s): SerpinPC
Therapeutic Area: Genetic Disease Product Name: SerpinPC
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: ApcinteX
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 14, 2022
Details:
The non-clinical data demonstrate systemic delivery of high doses of LB101 without hematological toxicity in non-human primates, resulting in the potential to achieve an enhanced therapeutic index, increased anti-tumor activity, and enable treatment for solid tumors.
Lead Product(s): LB101
Therapeutic Area: Oncology Product Name: LB101
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 12, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
